ArticleJournal of neuro-oncology2021

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.

Michael Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.